NR1H4 and steatosis: These include a dual activator of FXR and G protein-coupled receptor GPB AR1, which showed good results in a NASH mouse model with a strong reduction in steatosis and fibrosis [236,237], results similar to those obtained by an activator of FXR and transmembrane G protein-coupled receptor 5 (TGR5) [238,239].